Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder.
Bartakke
Sandip
S
Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abla
Oussama
O
Weitzman
Sheila
S
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab